Avantor, Inc. (NYSE:AVTR) Receives Consensus Recommendation of “Moderate Buy” from Brokerages

Shares of Avantor, Inc. (NYSE:AVTR) have been given a consensus recommendation of “Moderate Buy” by the sixteen research firms that are covering the firm, MarketBeat reports. Four analysts have rated the stock with a hold rating and twelve have given a buy rating to the company. The average 1-year target price among analysts that have updated their coverage on the stock in the last year is $26.29.

A number of equities research analysts have recently issued reports on AVTR shares. Deutsche Bank Aktiengesellschaft lifted their price target on shares of Avantor from $23.00 to $25.00 and gave the company a “hold” rating in a research report on Thursday, April 18th. Barclays cut their price objective on Avantor from $28.00 to $25.00 and set an “overweight” rating for the company in a research report on Friday, June 28th. Robert W. Baird cut their price objective on Avantor from $27.00 to $26.00 and set an “outperform” rating for the company in a research report on Monday, April 29th. Finally, Evercore ISI cut their price objective on Avantor from $28.00 to $27.00 and set an “outperform” rating for the company in a research report on Tuesday.

Institutional Trading of Avantor

Institutional investors have recently made changes to their positions in the stock. Fifth Third Bancorp grew its stake in shares of Avantor by 125.3% during the 4th quarter. Fifth Third Bancorp now owns 1,248 shares of the company’s stock valued at $28,000 after buying an additional 694 shares during the period. Livforsakringsbolaget Skandia Omsesidigt grew its stake in shares of Avantor by 565.5% during the 4th quarter. Livforsakringsbolaget Skandia Omsesidigt now owns 1,331 shares of the company’s stock valued at $30,000 after buying an additional 1,131 shares during the period. Gladius Capital Management LP purchased a new stake in shares of Avantor during the 4th quarter valued at $42,000. Montag A & Associates Inc. purchased a new stake in shares of Avantor during the 4th quarter valued at $43,000. Finally, TFO Wealth Partners LLC grew its stake in shares of Avantor by 203,100.0% during the 4th quarter. TFO Wealth Partners LLC now owns 2,032 shares of the company’s stock valued at $46,000 after buying an additional 2,031 shares during the period. 95.08% of the stock is owned by hedge funds and other institutional investors.

Avantor Price Performance

Shares of AVTR opened at $21.01 on Thursday. Avantor has a twelve month low of $16.63 and a twelve month high of $26.16. The stock’s 50 day moving average is $23.56 and its two-hundred day moving average is $23.79. The firm has a market capitalization of $14.27 billion, a PE ratio of 53.87, a P/E/G ratio of 2.15 and a beta of 1.32. The company has a current ratio of 1.61, a quick ratio of 1.05 and a debt-to-equity ratio of 0.94.

Avantor (NYSE:AVTR) last posted its quarterly earnings results on Friday, April 26th. The company reported $0.22 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.20 by $0.02. Avantor had a net margin of 3.79% and a return on equity of 13.01%. The company had revenue of $1.68 billion during the quarter, compared to the consensus estimate of $1.68 billion. During the same period last year, the firm earned $0.29 EPS. The company’s revenue for the quarter was down 5.6% on a year-over-year basis. Research analysts anticipate that Avantor will post 1.01 earnings per share for the current year.

Avantor Company Profile

Avantor, Inc engages in the provision of mission-critical products and services to customers in the biopharma, healthcare, education and government, advanced technologies, and applied materials industries in the Americas, Europe, Asia, the Middle East, and Africa. The company offers materials and consumables, such as purity chemicals and reagents, lab products and supplies, formulated silicone materials, customized excipients, customized single-use assemblies, process chromatography resins and columns, analytical sample prep kits, education and microbiology products, clinical trial kits, peristaltic pumps, and fluid handling tips.